NasdaqGM:TRVIPharmaceuticals
Trevi Therapeutics (TRVI): Evaluating Valuation After Appointing Veteran Biopharma CFO David Hastings
Trevi Therapeutics (TRVI) just named veteran finance executive David Hastings as its next Chief Financial Officer, effective January 6, 2026, a move that immediately sharpened investor focus on the stock’s trajectory.
See our latest analysis for Trevi Therapeutics.
The timing of Hastings’ appointment coincides with Trevi’s 90-day share price return of nearly 50 percent and roughly 180 percent year-to-date share price gain, which together indicate firmly building momentum, supported by a...